Erin G Nicholson1, Flor M Munoz2. 1. Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas. Electronic address: erin.nicholson@bcm.edu. 2. Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
Abstract
PURPOSE: Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. There are limited therapeutic options for children infected with RSV or influenza. This review focuses on therapeutics for RSV and influenza that are currently under clinical investigation. METHODS: This study used a systematic approach to identify prospective therapeutics in clinical trials and briefly reviewed those that are currently available for use in adults and children. FINDINGS: Overall, we found 14 investigational drugs currently in clinical trials for RSV and 20 investigation drugs currently in clinical trials for influenza. These candidates range in development from Phase I to Phase III clinical trials. IMPLICATIONS: Both RSV and influenza are targets for active therapeutic research, and promising candidates for both viruses are currently in clinical development.
PURPOSE:Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. There are limited therapeutic options for children infected with RSV or influenza. This review focuses on therapeutics for RSV and influenza that are currently under clinical investigation. METHODS: This study used a systematic approach to identify prospective therapeutics in clinical trials and briefly reviewed those that are currently available for use in adults and children. FINDINGS: Overall, we found 14 investigational drugs currently in clinical trials for RSV and 20 investigation drugs currently in clinical trials for influenza. These candidates range in development from Phase I to Phase III clinical trials. IMPLICATIONS: Both RSV and influenza are targets for active therapeutic research, and promising candidates for both viruses are currently in clinical development.
Authors: John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims Journal: Antiviral Res Date: 2019-04-08 Impact factor: 5.970
Authors: Ioannis N Mammas; Simon B Drysdale; Barbara Rath; Maria Theodoridou; Georgia Papaioannou; Alexia Papatheodoropoulou; Eirini Koutsounaki; Chryssie Koutsaftiki; Eleftheria Kozanidou; Vassilis Achtsidis; Paraskevi Korovessi; George P Chrousos; Demetrios A Spandidos Journal: Int J Mol Med Date: 2020-06-15 Impact factor: 4.101
Authors: Muhammad Mazhar Iqbal; Irfan Abid; Saddam Hussain; Naeem Shahzad; Muhammad Sohail Waqas; Muhammad Jawed Iqbal Journal: Sci Total Environ Date: 2020-06-09 Impact factor: 7.963